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Exosomes are endosomal-derived nanovesicles released by most cells types, including tumor cells, and
principally involved in intercellular communication in physiology and disease.
Tumor exosomes are gaining increasing interest in medicine and oncology as efﬁcient tools for the
delivery of deﬁned signals. Representing the acellular replicas of tumor cells, they contain a great variety
of bioactive molecules, such as proteins, RNA, miRNA and DNA. Their great ability to recirculate in body
ﬂuids and their structure allow them to transport their cargo to distant targets. Major studies have
shown that tumor exosomes convey information not only between tumor cells but also to other cell
types, including different immune cell components. There is increasing evidence that these nanovesicles
may contribute to cancer progression by inﬂuencing different immune cell types, likely blunting speciﬁc
T cell immunity and skewing innate immune cells toward a pro-tumorigenic phenotype. Because of this
functionand theadditional property todelivermolecular signalsmodulatingneoangiogenesis and stroma
remodeling, tumor exosomes are believed toplay a role in tumorprogressionby favoringmetastatic niche
onset.
This review outlines the recent knowledge on immune suppressive mechanisms mediated by tumor
exosomes. We will discuss our view on the role of these nanovesicular structures in cancer progression
and how their presence could interfere with cancer therapy.. Introduction
Tumor immunity, mostly involving speciﬁc T cells primed by
ntigenic determinants expressed in cancer cells and presented in
he appropriate immunological context, occurs in the initial phase
fneoplastic transformationandmay inﬂuencediseaseprogression
ndpatientprognosis.However, a complexnetworkofmechanisms
irectlymediatedby tumorcells orby thepro-inﬂammatoryassoci-
ted milieu, progressively blunts immune reactivity, thus resulting
n a silencing of adaptive immunity against cancer cells. This pro-
ess has been demonstrated to occur at tumor site, but also in
ocal or distant immune districts, such as draining lymph nodes
r the bone marrow, suggesting the presence of factors capable of
olding immune responses at systemic level. Soluble molecules or
irculating tumor-related cells can be involved in this process. Nev-
rtheless, an increasing interesthasbeen recently focusedon tumor
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exosomes as a relevant pathway for the delivery of deﬁned signals
from tumor site to distant organs. These nanovesicular organelles
are in fact hypothesized to represent an efﬁcient tool for tumor
cells to inﬂuence host responses without the need for a cell-to-
cell contact, thanks to their ability to recirculate and to transport a
rich array of bioactive molecules (including proteins, RNA, miRNA,
DNA).
In the present review we will outline the recent ﬁndings related
to tumor exosome-induced immune suppression, including the
studies dealingwith bona ﬁde exosomes but also those dealingwith
differently named nano-organelles, yet sharing the canonical fea-
tures of exosomes. The most important effects of tumor exosomes
on immunosuppression and disease progression are summarized
in Fig. 1.
2. Deﬁnition and discovery
The term “exosome” as a non-plasma membrane-derived vesi-
cle emerged for the ﬁrst time during studies of the “shedding”
process of the transferrin receptor (TfR) by reticulocytes undergo-
ing maturation [1–3]. In the years following these pioneer studies,
the releasemechanismof these vesicular structures has been inves-
tigated in different cell types, and common intercellular features
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sFig. 1. Potential effects of tumor exosomes on tum
n terms of shedding mechanisms and material composition, have
een soon identiﬁed. In fact, exosomes secreted by various cell
ypes have similarities such as the size, the endosomal origin [4] and
he presence of identical molecules. However, there are also clear
ifferences in their protein composition, as revealed by proteomic
tudies [5] and supposed function depending on the physiology of
he considered cell.
The  exosomes detectable in the extracellular compartment can
e visualized only by electron microscopy, revealing them as “cup
haped” membrane vesicles with a diameter of ±50–100 nm [6].
owever, they are acknowledged to represent a heterogeneous
opulation, with smaller vesicles often observed in the same prepa-
ation.
As a general concept, cells are known to secrete a large array of
esicular structures, ranging from membrane vesicles to apoptotic
odies [7]. Research groups focusing on exosomes have proposed
arious classiﬁcations mainly based on the different dimensions of
hese organelles as well as on density properties. A classiﬁcation
as also achieved by searching for reliable markers of endo-
omal origin. Nowadays, studies dealing with exosomes require
tandard visualization by electronmicroscopy, density gradient
entrifugation as well as characterization experiments involving
urity assessment of isolated fractions together with expression
f CD63, CD81 and other exosome-associated tetraspanins [8,9].
he achievement of such standard requirements has greatly con-
ributed to the reliability of exosome science.
Since their discovery in the 1980s, many years had to pass
ntil exosomes gained some visibility in the scientiﬁc commu-
ity. In 2005, Jennifer Couzin, a journalist of Science Magazine,
ppropriately described the ﬁrst encounter of cell biologists with
hese particles as “stumbling across the particles in their experi-
ents” [10]. Subsequently, a great effort has been devoted by an
ver growing number of investigating groups to dissect the world
ehind these small organelles, at ﬁrst dismissed as cellular “debris”,
ecreted into the extracellular space.unity, disease progression and cancer treatments.
Like  most non-transformed cells, also tumor cells release
exosomes whose composition can vary depending upon nature
and conditions of each individual cell. Exosome secretion is con-
stitutive and exacerbated in cancer cells, although it may  still be
modulated by microenvironmental milieu, inﬂuenced for instance
by growth factors [11], heat shock and stress conditions [12], pH
variations [13], and therapy [14]. Among the different released
vesicles, exosomes stand out for their intracellular endosomal
derivation, documented by the expression of endosomal markers
such as tetraspanin molecules and proteins that are enriched in
exosomal fractions, like hsp70 and MHC  class I molecules [7]. Still,
a unique marker identifying exosomes and discriminating them
among the other types of secreted vesicles has to be found. In fact,
this represents a major issue for the scientiﬁc community in need
of deﬁnition.
At ﬁrst the release of these nanovesicles was predominantly
investigated in immune cells, including B cells [15] and antigen pre-
senting cells [16], and the displayed characteristic features found by
the different research groups have since then been associated with
the term “exosome”. In contrast, many groups investigating the
same phenomenon in tumor cells of various histologies, including
ours, originally preferred to use the general term of “microvesicles”
[17–19]. Nevertheless, upon reconsideration of the initial evidence,
many tumor “microvesicles” were then found to display the com-
mon features of exosomes and have been assigned to this ﬁeld. The
discovery of exosomes carrying tumor antigens led to their poten-
tial exploitation as immune stimulators in cancer therapy [20–22].
However, an increasing number of studies showing their concomi-
tant suppressive potential has quenched the enthusiasm for such
strategies.3. Effects of tumor exosomes on immune cells
Different subpopulations of immune cells can be found in
primary tumor lesions as inﬁltrating components playing a
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avorable prognostic role [23–25]. However, the extent of bona
de anti-tumor immune cells detectable in situ is quantitatively
r qualitatively poor in metastatic lesions, with phenotypical and
unctional alterations suggesting defective activity. Simultane-
usly, immune responses against cancer cells detectable in the
eripheral blood of cancer patients lose their efﬁcacy and may
ven turn, in some cases, into mere indicators of tumor progression
26]. This evidence proves the onset of immunosuppressive mech-
nisms negatively modulating tumor immunity and nullifying its
bility to control tumor growth.
Cancer cells have been shown to shape the microenvironment
nd  affect the functionality of the immune system generally by
athways involving cell-to-cell contact and the release of suppres-
ive soluble factors [27]. However, an alternative mechanism has
ately emerged that involves the active release of exosomes by
umor cells [28,29]. Indeed, the evidence that exosomes of poten-
ial tumor origin can be abundantly found in peripheral blood
nd malignant effusions of patients in different cancer histologies
18,30,31], often associated with disease stage and tumor burden
32–34], suggests the involvement of these organelles in cancer
rogression [35].
Because  of their abundant expression of tumor antigens, tumor
xosomes were initially envisaged as an acellular source of anti-
enic determinants to be exploited in the design of cancer vaccine
trategies [21,22,31,36,20,37]. On the other hand, an increasing
umber of studies indicate that the physio-pathological role of
umor-derived exosomes might be more in favor of immune sup-
ression and tumor promotion.
.1.  Effects on anti-tumor effector T cells
One of the earliest evidence that tumor exosomes might con-
ribute in blunting cancer-speciﬁc T cells, at least in deﬁned phases
f their activation state, derives from studies focused on the expres-
ion by these organelles of a bioactive membrane-bound form
f FasL. Apoptosis via Fas/FasL interaction represents indeed one
f the major pathways controlling T cell homeostasis through
he selective elimination of over-reactive Fas-expressing T cells
38–41]. Several years ago, tumor cells, particularly from melanoma
nd colorectal carcinoma, were found to express FasL and to exploit
his expression as a novel pathway of immune escape [42,43]. In
002, as one of the groups investigating this phenomenon, we
ound that FasL was expressed in melanoma cells mostly at intra-
ellular level and with an endosome-associated pattern, and small
rganelles resembling melanosomes, initially quoted as microvesi-
les, expressed bioactive FasL as well. Characterization studies
hen revealed that melanoma cell supernatant contained vesicu-
ar organelles sharing with exosomes the size (50–100 nm), the
xpression of speciﬁc markers such as CD63 and the presence of
elanosomal proteins like gp100 and MART-1 [17]. In the following
ears many tumor cell lines of different histologies, including pan-
reatic [44], oral cancer [19], head and neck cancer [45] melanoma
46], colorectal carcinoma [18] and gastric cancer [47], have been
hown to share the ability to release pro-apoptotic exosomes, car-
ying not only FasL but also TRAIL on their surface. Altogether
hese data depicted a common scenario represented by the abil-
ty of tumor-released vesicles to eliminate activated T cells by a
imple ligand–receptor interaction. Noteworthy, this could also
e shown with exosomes isolated from biological ﬂuids, such as
lasma, serum and ascites [18,48,49], ascribing this mechanism a
otential relevance in cancer patients. This ﬁnding paved the way  to
 series of studies aimed at investigating the possibility that tumor
xosomes, thanks to their ability of recirculating at systemic level,
ould exert additional deleterious effects on the immune effec-
or cell compartment [17,18,50]. The presence of FasL on tumor
xosomes was also reported to mediate the down-modulationr Biology 22 (2012) 342– 349
of CD3- chain expression and subsequent TCR signaling impair-
ment in patients with ovarian carcinoma [51]. Other mechanisms
concerning tumor exosome-induced T cell apoptosis have been
recently described for Epstein–Barr Virus (EBV)-infected nasopha-
ryngeal carcinoma (NPC), whose exosomes eliminate EBV-speciﬁc
CD4+ lymphocytes through the binding of galectin-9 to the cognate
membrane receptor Tim-3, suggesting a role in the suppression
of Th1 cells at both the tumor and systemic levels [52]. Another
important pathway was  revealed by the studies of Clayton and
coworkers, who demonstrated that tumor exosomes contribute to
extracellular adenosine production, known to negatively regulate
local immune responses. In particular, functional CD39 and CD73
expressed by exosomes are capable of dephosphorylating exoge-
nous ATP and 5′AMP  to form adenosine, thus contributing to rise
the adenosine levels within the microenvironment [53].
3.2.  Myeloid cells and regulatory T cells
Tumor-derived exosomes can modulate other crucial com-
ponents of the immune response, impacting on the functional
properties of innate immunity. As an example, exosomes derived
from human melanoma and colorectal carcinoma cell lines were
shown to impair the capacity of circulating CD14+ monocytes
to differentiate into functional dendritic cells (DC) and to skew
them toward the differentiation into immunosuppressive elements
highly resembling the well-known population of myeloid-derived
suppressor cells (MDSC) [54]. The hallmarks of this in vitro-induced
new subset of MDSC were represented by the retention of CD14+
expression with concomitant low or absent levels of HLA-DR,
together with the ability to inhibit T cell proliferation and function
mostly through the release of TGF1 [55]. Interestingly, cells echo-
ing this phenotype could be detected by our group in the peripheral
blood of advanced melanoma patients; in fact, a signiﬁcant expan-
sion of CD11b + CD14+HLA-DR-/low TGF-secreting cells, was found
in the peripheral blood of stage IV melanoma patients with respect
to healthy donors, in association with a reduced ability to mount
CD8+ T cell-mediated immune response upon vaccine admin-
istration [56]. Interestingly, the frequency of CD14+HLA-DR-/low
TGF-secreting cells is increased already in peripheral blood of
IIb–IIIc stage melanoma patients, suggesting that systemic MDSC
expansion is an early event in this type of cancer, in contrast to regu-
latory T (Treg) cells, whose expansion is detectable only in advanced
disease (P. Filipazzi, personal communication). These ﬁndings led to
the hypothesis that melanoma exosomes might be involved in driv-
ing MDSC expansion by possibly accumulating in the bone marrow,
where they might inﬂuence myelopoiesis toward the differentia-
tion of immunosuppressive pro-tumorigenic cell subsets [57].
CD14+HLA-DR-/low MDSC have also been found in peripheral
blood of patients affected by other types of cancer, including
hepatocellular carcinoma [58], bladder cancer [59] and multiple
myeloma [60]. In these latter studies a direct link between tumor
exosomes and the generation of monocyte-derived MDSC has not
been investigated. However, we  cannot exclude that exosomes
secreted by tumor cells might contribute to this phenomenon.
The  interaction between the cellular immune system and
cancer-derived exosomes can also directly support Treg expansion
as well as their suppressive functions. In a recent study, Szajnik et al.
reported that exosome-like microvesicles isolated from ascites and
blood of cancer patients, induce a transition of CD4+CD25− T cells to
CD4+CD25+Foxp3+ Treg via phosphorylation of Smad2/3 and Stat3,
thereby upregulating their suppressor functions and resistance to
apoptosis through a TGF- and IL-10-dependent mechanism [61].
Similarly, exosomes expressing TGF derived from the malignant
effusion of cancer patients were reported to promote the increase in
number and functionality of Treg in vitro [62]. Another evidence has
been reported by Clayton et al., who showed that exosomes isolated
 Cance
f
p
a
e
h
i
i
m
i
g
p
s
t
a
s
T
g
a
t
s
t
o
a
t
m
f
m
6
c
s
t
p
M
m
C
t
s
2
r
3
s
e
c
t
n
i
c
o
d
a
e
m
c
m
m
s
N
h
m
a
oP. Filipazzi et al. / Seminars in
rom different tumor cell lines carry surface TGF and inhibit T cell
roliferation by skewing IL-2 responsiveness in favor of Treg and
way from cytotoxic cells [63]. It is worth mentioning that TGF-
xpressing exosomes can also be involved in physiological immune
omeostasis. In fact, a recent study indicates that TGF expressed
n thymic exosomes is required for the generation of Foxp3+ Treg
n peripheral tissues, such as lung and liver, and participate in the
aintenance of physiological immune tolerance [64].
The  role of tumor exosomes in promoting the expansion of
mmunoregulatory cell components are beginning to be investi-
ated also in in vivo murine models, representing a crucial step for
roving a true involvement of this pathway in immunosuppres-
ion and tumor progression. In this regard it should be pointed out
hat one major hurdle of this type of studies has been so far to
ssess pharmacokinetics of the injected exosomes that, due to their
mall dimension, might behave differently compared to whole cells.
echnical advances of the last years have enabled the investigating
roups not only to trace exosomes after in vivo administration but
lso to analyze the interaction pathways with host cells, an issue
hat is still poorly investigated.
Most  of the experimental evidences on the immunosuppres-
ive role of tumor exosomes point to a potential involvement in
he expansion of MDSC, while less information about the impact
f these organelles on Treg, once injected in vivo, are presently
vailable. Immune suppressive pathways generated by adoptively
ransferred tumor exosomes have been observed in the TS/A mam-
ary tumor murine model, where injected nanovesicles were
ound to interact with CD11b+ myeloid precursors in the bone
arrow (BM) and to block BMDC differentiation by inducing IL-
 production and Stat3 phosphorylation [65]. Similarly, in a breast
arcinoma model, tumor-derived exosomes were demonstrated to
kew BMDC differentiation toward an MDSC phenotype promoting
umor progression, through a prostaglandin E2 and TGF-mediated
athway [66]. Recent data also demonstrated a pivotal role for
yD88 in tumor exosome-mediated expansion of MDSCs and pro-
otion of lung metastasis in C57BL/6j (B6) mice [67]. Likewise,
halmin et al. [68] reported in both murine and human settings,
hat Hsp72 expressed on the surface of colon cancer-derived exo-
omes induces IL-6 release from MDSC in a Toll-like receptor
/MyD88/Stat3-dependent manner, even if the role of Toll-like
eceptor 2 in this process remains unclear [69,70].
.3. NK cells
Tumor-derived exosomes can also promote tumor immune eva-
ion by interfering with NK cells. Indeed, NKG2D ligand-containing
xosomes derived from human breast cancer and mesothelioma
ell lines were reported to directly interact with NK cells, leading
o a signiﬁcant reduction in NKG2D expression, resulting in sig-
iﬁcant defects of NK effector functions [12,71,72]. Additionally,
t has been reported that treatment of NK cells with exosomes
ontaining MICA*008 molecules mediated the down-regulation
f NKG2D and a marked reduction in NK cytotoxicity, indepen-
ent of NKG2D ligand expression by the target cells [73]. Studies
imed at evaluating the effects of tumor exosomes in murine mod-
ls have shown that exosomes produced by TS/A or 4T.1 murine
ammary tumor cells can favor the growth of implanted tumor
ells in both syngeneic BALB/c and nude mice by blocking IL-2-
ediated activation of NK cells. Moreover, the NK cytolytic activity
ediated by perforin and granzyme B was directly inhibited by
uch exosomes in ex vivo and in vitro approaches. Inhibition of
K cell proliferation was also mediated by exosomes produced by
uman breast cancer and melanoma cell lines [74]. The involve-
ent of tumor exosomes in decreasing NK cell activity has been
lso assessed using exosome-like microvesicles isolated from sera
f acute myeloid leukemia patients. The authors provide evidencer Biology 22 (2012) 342– 349 345
for  microvesicle-mediated suppression of NK cell activity and
NKG2D down-regulation. Analysis of isolated organelles revealed
the presence of membrane-associated TGF, whose neutraliza-
tion by speciﬁc antibodies was associated with reversed inhibitory
effects in in vitro studies. Interestingly, also the addition of IL-15 to
NK cells protected them from these adverse effects [75].
4.  Tumor-derived exosomes in cancer progression
As whole cancer cells, tumor exosomes can promote disease
progression not only by evading from immunosurveillance, but
also by feeding autocrine loops, stimulating angiogenesis, modu-
lating stromal cells, and remodeling the extracellular matrix [76].
Indeed, the cargo of molecules composing these vesicular struc-
tures secreted by tumor cells contains an ever growing number
of proteins and genetic material that is apparently exploited in
different ways, yet all merging in promotion of tumor growth.
4.1.  Tumor exosomes as protein and genetic messengers
In their study on melanoma-derived exosomes, Hood et al.
[77] described the pro-angiogenic potential of such vesicles,
that appeared to rapidly stimulate the production of endothelial
spheroids and endothelial sprouts in a dose-dependent manner.
The obtained results suggested a role of tumor exosomes in pro-
moting endothelial angiogenic responses, sustaining metastatic
potential. The same group reported later that melanoma-derived
exosomes share the ability to condition sentinel lymph nodes in
becoming remote niches conducive to melanoma cell recruitment
and growth, extracellular matrix deposition and vascular prolifer-
ation [78].
One  of the major factors that can be hypothesized to con-
fer pro-angiogenic activity to tumor exosomes is represented
by the proteins of the tetraspanin family, a large set of trans-
membrane molecules highly enriched in tumor exosomes [79].
Tetraspanins have still a controversial role in cancer, being reported
both to promote and suppress tumor invasion and metastasis, in
dependence on the multimolecular transmembrane complex called
tetraspanin-enriched microdomain (TEM). An important feature of
these proteins is their ability to modify the cell membrane structure
and function [80]. Recent evidence has shown that tetraspanins
on tumor exosomes are able to promote tumor growth by their
capacity to induce systemic angiogenesis in tumors and tumor-
free tissues [81]. In particular, in a rat adenocarcinoma model,
the tetraspanin Tspan8 contributed to a selective recruitment of
proteins and mRNA into exosomes, including CD106 and CD49d,
both of which were implicated in the binding and internaliza-
tion of exosomes by endothelial cells. Upon internalization of
Tspan8-CD49d complex-containing exosomes, Nazarenko and col-
laborators observed an induction of several angiogenesis-related
genes, including von Willebrand factor, Tspan8, VEGF, chemokines
CXCL5 and MIF, chemokine receptors CCR1, and VEGF receptor 2.
Moreover, the uptake of Tspan8-CD49d complex-containing exo-
somes by endothelial cells (EC) was accompanied by enhanced EC
proliferation, migration, sprouting and maturation of EC progen-
itors [82]. There is also evidence that tumor-derived exosomes,
incorporating the Notch ligand Delta-like 4 (Dll4), can have an
essential role in vascular development and angiogenesis. These
Dll4-containing exosomes confer a tip cell phenotype to the EC,
which results in a high Dll4/Notch-receptor ratio, low Notch sig-
naling and ﬁlopodia formation. This reversal in phenotype appears
to enhance vessel density in vitro and branching in vivo [83].
Exosome  composition can vary depending upon the condi-
tions of the secreting cells. It has been recently shown that
during hypoxia tumor cells display an increased pro-angiogenic
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nd metastatic potential, that is mediated at least in part by exo-
omes. Proteomic analysis revealed in fact that 50% of the secreted
roteins involved in this process were found to be associated with
xosomes [84]. Hypoxic glioblastoma cells were also shown to
elease microvesicles with exosome-like characteristics containing
issue Factor that induced activation of endothelial cells resulting
ltimately in tumor promoting neoangiogenesis [85].
It  has been shown that the ability of tumor exosomes to
lter tumor microenvironment depends on their protein- and
NA-based cargo. Skog and colleagues [86] demonstrated that
lioblastoma exosomes can modify the surrounding normal cells
y changing their translational proﬁle. Indeed, exosomes contain-
ng mRNA, miRNA and angiogenic proteins, including angiogenin,
GF, IL-6, IL-8, TIMP-1, VEGF and TIMP-2, are taken up by brain
icrovascular endothelial cells, thereby stimulating endothelial
ubule formation or proliferation of other glioma cells. Addition-
lly, it has been reported that through exosomal secretion and
ptake, a human tumor virus can induce the transfer of a viral onco-
rotein, signal transduction molecules and virus-encoded miRNAs
nto multiple cell types, thereby activating several cell-signaling
athways. For instance, exosomes released from nasopharyngeal
arcinoma (NPC) cells harboring latent EBV and containing the
atent membrane protein 1 (LMP1), were able to inhibit immune
unction. On the other hand, this transfer of LMP1 into recipient
ells led to activation of growth-signaling pathways [87]. Recent
ata have evidenced that exosomes produced by normal cells can
lso contribute to tumor progression. Macrophage-derived exo-
omes are able to shuttle proteins or miRNAs into adjacent cells
ithin the microenvironment. In particular, the study published
y Yang et al. demonstrates that exogenous miRNA (miR-223)
ransfected into IL-4-activated M2  macrophages is internalized by
o-cultivated breast cancer cells, thus promoting the invasiveness
f breast cancer cells in vitro [88].
.2. Modulation of stroma and extracellular matrix
Another relevant feature of exosomes derived from different
ancer cell lines, including mesothelioma, bladder, breast and col-
rectal cancer cells, is represented by the capability to modulate
tromal cell differentiation. Indeed, it has been shown that the com-
lex TGF-transmembrane proteoglycan betaglycan, expressed at
he exosome surface, is able to elicit Smad-dependent signal-
ng. Thereby a program of differentiation of ﬁbroblasts toward
 myoﬁbroblastic phenotype is initiated leading to an altered
troma that usually supports tumor growth, vascularization and
etastasis [89]. Likewise, a role for breast cancer exosomes in
onversion of adipose tissue-derived mesenchymal stem cells into
yoﬁbroblast-like cells has been reported. As in the ﬁrst citation
89], these authors also found an implication for TGF, secreted
y the cells after encounter with exosomes, and the activation of
mad-mediated pathway [90].
Recently, exosomes derived from gynecologic neoplasias, were
ound to contain metalloproteinases that increase extracellular
atrix degradation and augment tumor invasion into the stroma
91]. On the other hand it has been shown in a rat pancreatic adeno-
arcinoma model that tumor-derived exosomes could contribute to
etastatic niches, together with soluble factors. This process was
ependent on CD44v6, which is required for assembling a soluble
atrix that, in cooperation with exosomes, promotes leukocyte,
troma and endothelial cell activation in the (pre)metastatic organ
92]..3. Autocrine role of tumor exosomes
The secretion of soluble factors, such as growth factors,
ytokines and chemokines, by the growing tumor to sustain itsr Biology 22 (2012) 342– 349
own  growth is nowadays a well established issue [93–96]. The
subsequent discovery of exosomes raised the question about their
potential beneﬁt for the secreting tumor cells. Studies aimed at
investigating a role for these microvesicular structures in autocrine
stimulation of the cancer itself showed that indeed tumor exo-
somes add up to the pro-tumoral effects of soluble factors by
the transfer of molecules requiring to be bound to carriers, such
as exosomes. One key study showed the intercellular transfer of
the oncogenic receptor EGFRvIII by tumor exosomes to glioma
cells lacking this receptor, thereby contributing to morphological
transformation and anchorage-independent growth [97]. Another
recent report describes a role for amphiregulin (AREG), an EGFR
ligand, in human colorectal and breast cancer cell invasion. Here
the authors showed that full-length AREG carried by tumor exo-
somes increased invasiveness ﬁve-fold over equivalent amounts of
recombinant AREG [98].
Like all exosomes, also tumor exosomes are enriched in
expression of the so-deﬁned canonical exosome markers, such as
members of the tetraspanin family of proteins (CD9, CD81 and
CD63), but also small Rab GTPases, lately discovered as master reg-
ulators of vesicle trafﬁc. Among these, the two isoforms of Rab27
have been shown to control exosome secretion in HeLa cervical can-
cer cells [99]. In breast cancer cells, Rab27B appears as key factor
for invasive tumor growth. Hendrix et al. propose that this GTPase
mediates vesicle exocytosis and subsequent HSP90 release into
the microenvironment, in turn facilitating the binding of growth
factors to their receptors and ultimately leading to cell cycle tran-
sition from the growth factor–sensitive G1-S-phase [100].
5.  Potential interference of tumor exosomes with cancer
therapies
An  indirect mode of contributing to disease progression and
consequently to the generation of immunosuppressive circuits,
spreading and metastases development could be represented by
interference with cancer therapy. Tumor exosomes appear to have
found their way  into the different mechanisms exploited by cancer
cells to counter therapeutic agents.
A pioneer study by Luciani and collaborators suggested several
years ago that endosomal vesicles of melanoma, adenocarcinoma
and lymphoma cells could be responsible for sequestering cyto-
toxic drugs such as cisplatin, 5-ﬂuorouracil, and vinblastine, thus
reducing the anti-tumor potential of chemotherapy [101]. This
hypothesis was subsequently strengthened by Chen et al. [102],
with in vitro experiments showing that melanosomes contributed
to the refractory properties of melanoma cells by sequester-
ing cytotoxic drugs and increasing melanosome-mediated drug
export. Similarly, in 2005, Safei and coworkers showed that
cisplatin-resistant ovarian cancer cells were able to expel this
chemotherapeutic drug through enhanced release of exosomes,
which expressed higher levels of the cisplatin export transporters
MRP2, ATP7A and ATP7B. In these tumor cells, resistance to cis-
platin was  accompanied by higher levels of genes whose products
function in membrane fusion and vesicle trafﬁcking, a reduction
of the lysosomal compartment, where this drug usually becomes
concentrated, and an abnormal export of the drug by exosomes
[103]. Resistance to cisplatin has been also associated to increased
expression of annexin A3 by ovarian cancer cells and this molecule
could be found in culture medium of the same cells. Electronmi-
croscopy studies showed that high expression of annexin A3 was
linked to increased amount of vesicles in the cytoplasm and these
were also detectable as exosomes in culture medium, illustrating
another evidence for exosome-mediated countering of cisplatin
action [104].
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Potential effects on tumor exosome production were also eval-
ated in radiation-treated cancer cells. Prostate cancer patients are
ften treated using radiation therapy that, according to the authors,
nduces premature cellular senescence accounting for most of the
lonogenic death in prostate cancer cells [105]. In this context
he same group assessed that treatment-induced senescent cells
ecrete increased amounts of exosome-like vesicles and that this
henomenon was dependent on activation of p53, whose involve-
ent in the regulation of exosome release was previously shown
106]. Exosome-like vesicles may  thus comprise an important and
reviously unrecognized feature of premature cellular senescence
107]. In contrast, Khan et al. showed that irradiation of tumor cells
ed to changes in exosome composition rather than in the secretion
ate. Treatment of cervical carcinoma cells with sublethal doses of
rradiation resulted in increased survivin content in exosomes.
Since  extracellular survivin was able to enhance cellular pro-
iferation, survival and tumor cell invasion, one could hypothesize
 role for survivin-carrying exosomes in sustaining the recovery
rom stress-induced injury, as in the case of irradiation [14]. A par-
icipation of tumor exosomes has been also described in countering
ntibody-mediated cancer therapies, in particular for Trastuzumab
n breast cancer treatment. In this regard, HER2-expressing exo-
omes isolated from sera of breast cancer patients bound to this
ntibody and autologous exosomes inhibited Trastuzumab activ-
ty on SKBR3 proliferation [11]. By binding of tumor-reactive
ntibodies, breast cancer exosomes were also shown to reduce
ntibody-dependent cytotoxicity (ADCC) of immune effector cells,
ne of the fundamental anti-tumor reactions of the immune system
108]. Similarly, in an in vitro model of aggressive B cell lymphoma,
D20-expressing tumor exosomes were able to consume comple-
ent and shield target cells from antibody attack, resulting in
rotection from complement-dependent cytolysis (CDC) as well as
DCC [109].
.  Concluding remarks
As  vesicular structures released into the extracellular space,
umor exosomes are receiving increasing attention for their role
n intercellular communication. It is important to underline that
very study dealing with these organelles nowadays requires accu-
ate and detailed evaluation to assess the actual presence of “true”
xosomes in the isolated fractions prior to use for more spe-
iﬁc research. This identiﬁcation requires techniques based on
ifferential and gradient high speed centrifugations, immuno-
lectronmicroscopy, purity assessments by Western blotting and
etection of canonical markers by ﬂow cytometry of exosomes.
hese ﬁrst steps are fundamental not only to exclude contamina-
ions derived from other cell compartments but also to assess the
resence of bona ﬁde exosomes, based on recent ﬁndings and stan-
ard protocols existing for exosome handling. Nowadays, technical
dvances in this ﬁeld and agreements on the deﬁnition of exosomes
eached by the scientiﬁc community, allow distinction of this kind
f organelle from others, giving investigators the opportunity to
tudy “state-of-the-art” exosomes.
As a ten-years experienced group investigating tumor exo-
omes, we believe that although many secrets of these fascinating
esicles have been disclosed, there are as many still untold. Appar-
ntly, we are at the beginning of a long way to go, but, as outlined
n this review, observed features and effects mediated by tumor
xosomes start to merge into a single, albeit multifaceted claim. In
act, to cite some examples, the elimination of activated T cells by
ro-apoptotic molecules together with immunosuppressive effects
ransmitted by TGF containing tumor exosomes are recurrent
ndings of different groups working on distinct cancer histologies,
nderlining the importance of these achievements.r Biology 22 (2012) 342– 349 347
In  conclusion we  would like to point to the enormous poten-
tial of tumor exosomes as mediators of immunosuppression and
disease progression in cancer patients. Dissection of the pathways
leading to these pro-tumorigenic features will greatly enhance our
understanding in this context offering at the same time a great
opportunity for the identiﬁcation of new targets for cancer ther-
apies.
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